Metastasis is the major cause of cancer morbidity, but strategies for direct interference with invasion processes are lacking. Dedifferentiated, late-stage tumor cells secrete multiple factors that represent attractive targets for therapeutic intervention. Here we show that metastatic potential of oncogenic mammary epithelial cells requires an autocrine PDGF/PDGFR loop, which is established as a consequence of TGF-β–induced epithelial-mesenchymal transition (EMT), a faithful in vitro correlate of metastasis. The cooperation of autocrine PDGFR signaling with oncopgenic Ras hyperactivates PI3K and is required for survival during EMT. Autocrine PDGFR signaling also contributes to maintenance of EMT, possibly through activation of STAT1 and other distinct pathways. Inhibition of PDGFR signaling interfered with EMT and caused apoptosis in murine and human mammary carcinoma cell lines. Consequently, overexpression of a dominant-negative PDGFR or application of the established cancer drug STI571 interfered with experimental metastasis in mice. Similarly, in mouse mammary tumor virus–Neu (MMTV-Neu) transgenic mice, TGF-β enhanced metastasis of mammary tumors, induced EMT, and elevated PDGFR signaling. Finally, expression of PDGFRα and -β correlated with invasive behavior in human mammary carcinomas. Thus, autocrine PDGFR signaling plays an essential role during cancer progression, suggesting a novel application of STI571 to therapeutically interfere with metastasis.

Introduction

Carcinomas account for more than 80% of human cancers, generated through a multistep process (1) eventually leading to metastasis, the major cause of cancer morbidity. In normal epithelia, homeostasis, differentiation, and organ integrity are regulated by interactions among epithelial cells, the extracellular matrix, and adjacent nonepithelial cells. Normal epithelial cells cannot digest and migrate through the basement membrane (2) and undergo apoptosis upon displacement from their substratum (anokia; ref. 3). During tumor progression, cancer cells gain anchorage independence and the ability to transmigrate tissues, a prerequisite for metastasis to distant sites (4, 5). Multiple molecular players contribute to the acquisition of invasive properties by tumor cells (1, 6), but we are only beginning to understand the molecular mechanisms involved.

One of the key players in late-stage tumor progression is TGF-β (7, 8), which promotes metastasis in several murine tumor models (9–13). Loss of TGF-β receptor II (TGF-βRII) also correlates with good prognosis in colon carcinoma patients with DNA mismatch repair deficiency (microsatellite instability or MIN type; ref. 14). Likewise, acquisition of metastatic potential in skin tumors is associated with activation of TGF-β signaling through loss of the natural TGF-βR decoy receptor NMA/Bambi (15). In normal epithelial cells, TGF-β causes cell-cycle arrest and apoptosis, which contributes to the tumor-suppressive function of TGF-β signaling in early stages of tumorigenesis (7, 9). During late-stage tumor progression, this antiproliferative response to TGF-β is lost, for instance, through inactivating mutations in TGF-βRII (16) and Smad4 (17) in human colon and pancreatic carcinomas, respectively. In most tumor types, including mammary carcinomas, however, mutations in TGF-βR or Smads are rare, and tumor cells commonly abolish the antiproliferative function of TGF-β while remaining responsive to the factor. This may occur through loss/mutation of TGF-β–regulated tumor suppressors (such as p16INK4a; ref. 18) and/or cooperation with hyperactive Ras (7, 19).

Consistent with the ability of oncogenic Ras to overcome the TGF-β–mediated proliferation arrest, receptor tyrosine kinases (RTKs; ref. 20), and Ras family proteins (21, 22) are mutated, amplified, or hyperactivated in many human cancers. Furthermore, in several epithelial cell models, including the murine mammary epithelial cell line EpH4, metastatic potential requires the cooperation of TGF-β signaling with hyperactive ERK/MAPK signaling, caused by oncogenic RTKs (e.g., HER2), Ras, or Raf (23–26). In Ras-transformed EpH4 cells (EpRas cells), metastatic potential strictly correlated with the ability to undergo TGF-β–induced epithelial-mesenchymal transition (EMT) (27, 28). EpH4 cells that are protected from apoptosis but lack Ras-dependent MAPK hyperactivation are devoid of metastatic potential and fail to undergo persistent changes in epithelial marker gene expression (19, 28). Rather, these cells display a migratory phenotype in response to TGF-β, which is distinct from EMT and was termed “scattering.” As originally defined (2), EMT involves transdifferentiation of epithelial cells to fibroblastoids, invasive cells with the ability to transmigrate the basal lamina, showing a profoundly altered, mesenchymal gene expression program (19, 29). Recently, multiple developmental signaling pathways and transcription factors (Wnt, Notch, Hedgeshog, NF-kB, Snail superfamily, Twist) were shown to contribute to EMT and promote tumor cell invasion at the same time (reviewed in

Nonstandard abbreviations used: dnP, dominant-negative PDGFR; EMT, epithelial-mesenchymal transition; EpRas cell, Ras-transformed EpH4 cell; FDGP, factor-dependent continuous cell line; MMTV, mouse mammary tumor virus; RTK, receptor tyrosine kinase; TGF-βRII, TGF-β receptor II.

Conflict of interest: The authors have declared that no conflict of interest exists.


Autocrine PDGFR signaling promotes mammary cancer metastasis

Martin Jechlinger,1 Andreas Sommer,1 Richard Moriggl,1 Peter Seither,2 Norbert Kraut,3 Paola Capodieci,4 Michael Donovan,4 Carlos Cordon-Cardo,5 Hartmut Beug,1 and Stefan Grünert1

1Research Institute for Molecular Pathology, Vienna, Austria. 2Boehringer Ingelheim Pharma KG, Genomics Group, Biberach, Germany. 3Boehringer Ingelheim Austria GmbH, Department of Lead Discovery, Vienna, Austria. 4Aureon Laboratories, Yonkers, New York, USA. 5Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
refs. 30, 31). In many human carcinomas, however, detection of EMT can be difficult due to its frequently transient nature (32).

Recently we employed expression profiling to find genes selectively upregulated during EMT, identifying multiple genes upregulated during late-stage tumor progression (29). This metastasis-specific gene set included PDGF, components of the PDGFR signaling pathway, and known target genes (29), suggesting establishment of an autocrine PDGF/PDGFR loop in an EMT-specific fashion. So far, autocrine PDGF signaling has almost exclusively been described in nonepithelial tumors, e.g., gliomas (33). While expression of PDGF correlates with advanced tumor stages and unfavorable prognosis in human breast carcinomas (34, 35), PDGF produced in carcinomas is generally thought to act on the nonepithelial tumor stroma, for instance, by promoting angiogenesis (36, 37).

Here, we show that an autocrine PDGF signaling loop coincides with TGF-β–induced EMT in mammary epithelial cells and mammary tumors in mouse mammary tumor virus–Neu (MMTV-Neu/TGF-β) transgenic mice. Autocrine PDGF signaling essentially contributes to EMT, since its blockade abolishes TGF-β–induced EMT in EpRas cells, inducing apoptosis instead. This is due to interference with PDGFR-dependent hyperactivation of PI3K—the major signaling target of the PDGFR in vivo (38, 39)—which is required for apoptosis protection during EMT (24). Furthermore, interference with PDGF signaling abolished the established mesenchymal phenotype in EpRasXT cells and caused apoptosis in human mammary carcinoma cell lines. These findings are of physiological relevance, since inhibition of PDGF signaling by STI571 or expression of a dominant-negative PDGFR (dnP) strongly reduced the metastatic potential of EpRas cells in an in vivo metastasis assay.

Figure 1
EMT-specific upregulation of PDGFR pathway genes generates an autocrine PDGF/PDGFR loop. (A) Regulation of PDGFR pathway genes in various cell pairs based on EpH4 mouse mammary epithelial cells that undergo TGF-β–induced alterations in epithelial plasticity (see ref. 29). Two cell pairs underwent EMT in response to TGF-β (yellow), 2 underwent reversible scattering (green), and 2 cell pairs served as oncogene controls (black). Shown are the oncogenes cooperating with TGF-β, the predominant signaling pathways activated, and the fold regulation of 5 PDGF pathway genes (red: upregulation; pink: no significant regulation, blue: downregulation). (B) Concentrated, serum-free supernatants from EpRas and EpRasXT cells were tested on huPDGFR-A/FDCP-1 cells for mitogenic activity ([3H]thymidine incorporation). Specificity of the mitogenic response for PDGF was verified by addition of saturating amounts of a neutralizing α-PDGF-A/B antibody.

Figure 2
Increased metastasis induced by RTK plus TGF-β signaling in a transgenic mammary carcinoma model correlates with EMT and invasion. (A) Spontaneous formation of lung metastases in transgenic mice bearing a normal (MMTV-Neu) or constitutively active (MMTV-C.A.-Neu) EGFR 2 (HER2) under the control of the MMTV promoter (40) before or after breeding MMTV-TGF-β1 transgenic mice (Neu/TGF-β1, C.A.-Neu/TGF-β1). Thirty to 36 mice per group were analyzed for metastasis formation, and differences in numbers of metastases between the different groups were significant (P < 0.01). (B) Primary tumors from MMTV-Neu mice or MMTV-Neu × MMTV-TGF-β1 mice were subjected to cryosectioning and histological staining. (C) Cryosections from the above-described tumors were stained with antibodies against vimentin (red, left panels) or tenascin C (green) plus CD31 to indicate endothelial cells (red; see Methods). DNA (nuclei) stained with DAPI (blue). MMTV-Neu tumors expressed tenascin C only in CD31-positive endothelial cells from tumor blood vessels, while the MMTV-Neu × MMTV-TGF-β1 tumors clearly expressed tenascin C in the tumor cells themselves. Original magnification, ×40 (B and C). (D) Tumors from MMTV-Neu or MMTV-Neu × MMTV-TGF-β1 mice were processed for mRNA extraction and real-time PCR, using oligonucleotide primers for PDGF-A, PDGF-B, and the PDGFR target gene JE/MCP-1. The amount of mRNA obtained for double transgenic tumors was higher in all cases (P < 0.05).
Finally, expression of both PDGFRα and -β was not detectable in normal human mammary tissue but correlated with an invasive phenotype in primary human mammary carcinomas. Our results thus establish a cell-autonomous, functional role of the PDGFR during metastasis of mammary carcinoma cells, suggesting the PDGFR as a potential target for pharmacological intervention to reduce the metastatic potential of breast cancer.

Results

TGF-β induces an autocrine PDGF loop during EMT. Using comparative expression profiling of 7 EpH4-based cell pairs undergoing EMT, scattering, or oncogenic transformation, PDGFR signaling was found to be upregulated exclusively during EMT (Figure 1A; ref. 29; for a detailed description of cell types used, see Supplemental Methods; Supplemental material available online with this article; doi:10.1172/JCI24652DS1). In mesenchymal EpRasXT cells, increased expression of PDGF-A, PDGFRα and -β, and STAT1 and -2 chemokines (JE/MCP-1 and KC/Gro-1; known as PDGFR target genes) was observed, as compared with their epithelial counterparts. To verify that the PDGF induced during EMT was secreted and bioactive, we employed murine hematopoietic cells that express the human PDGFR during metastasis of mammary carcinoma cells, suggesting the PDGFR as a potential target for pharmacological intervention to reduce the metastatic potential of breast cancer.

Table 1
Analysis of 16 normal mammary tissues, 45 intraductal carcinomas, and 93 invasive carcinomas for their anti-PDGFRα or anti-PDGFRβ immunostaining levels

<table>
<thead>
<tr>
<th></th>
<th>Anti-PDGFRα staining</th>
<th>Anti-PDGFRβ staining</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Undetectable</td>
<td>Low to moderate</td>
</tr>
<tr>
<td>Normal breast, no. (%)</td>
<td>16 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Intraductal carcinoma, no. (%)</td>
<td>32 (71.1)</td>
<td>13 (28.9)</td>
</tr>
<tr>
<td>Invasive carcinoma, no. (%)</td>
<td>32 (34.3)</td>
<td>45 (48.4)</td>
</tr>
</tbody>
</table>

Staining was classified as undetectable (as shown in Figure 3, A and B), low to moderate, or intense (as shown in Figure 3, C and D).
PDGF signaling in EpXT cells would enhance PI3K pathway activity by measuring p-AKT levels. In epithelial EpRas cells, neither PDGF nor PDGF-neutralizing antibodies altered p-AKT levels (Figure 4A). In contrast, EpRasXT cells showed a 2.5-fold higher PI3K activity than EpRas cells, which was further enhanced 2-fold by addition of PDGF (Figure 4A). Treatment with neutralizing PDGF antibody reduced PI3K activity in EpRasXT cells to the level of EpRas cells, while nonimmune antibodies failed to affect PI3K activity. Similar results were obtained with a specific inhibitor of the PDGFR tyrosine kinase and with the approved cancer drug STI571 (Gleevec), which inhibits several RTKs, including the PDGFR (42). PDGF also activated STAT1 in EpRasXT cells (39) (Supplemental Figure 1, A and B), which is known to contribute to breast cancer (39, 43). Indeed, both STAT1 expression and its activation by PDGF occur exclusively in cells able to undergo EMT (Supplemental Figure 1C), consistent with a possible role of STAT1 during tumor progression.

In contrast to activating the PI3K and STAT1 pathway, PDGF had no reproducible effect on ERK/MAPK activity in either EpRas or EpRasXT cells (data not shown).

**Figure 4**

Interference with autocrine PDGF signaling in EpRas cells prevents EMT by causing apoptosis. (A) EpRas and EpRasXT cells were treated with PDGF, VEGF (control, VEGFR pathway not altered in EpRasXT cells), PDGF-neutralizing antibodies (α-PDGF-Ab), 2 nonimmune control antibodies (Contr. Ab 1 and 2), the tumor drug STI571, or a specific PDGFR tyrosine kinase inhibitor (PDGFR inh; see Methods). Levels of p-AKT were determined by Western blot analysis. For normalization, blots were stripped and reprobed for total AKT. Signals were quantified by densitometry, normalized to levels of untreated EpRas cells, and shown as histograms. Data from 3 independent experiments are represented as mean ± SD. (B) EpRas cells were seeded into collagen gels and induced or not induced to undergo EMT by addition of TGF-β, in the presence or absence of neutralizing PDGF antibodies (α-PDGF), no immune antibodies (Contr. Ab), or STI571. Cultures were photographed after 7 days. (C) Similar collagen cultures were subjected to in situ TUNEL staining (green) and counterstaining for DNA (red). Lumina of polarized epithelial structures (yellow arrows), spindle-shaped mesenchymal cells (white arrows), and TUNEL-positive nuclei (green arrows) are indicated. Original magnification, ×10 (B) and ×40 (C). (D) Quantification of the data in B (>300 cells from several gel structures were evaluated for TUNEL and DAPI staining).
superinduced the PI3K pathway in EpRasXT cells (Figure 4A), we tested whether interference with PDGFR/PDGFR signaling would affect cell viability during EMT. EpRas cells were cultured in collagen gels for 4 days and induced to undergo EMT by TGF-β, in either the presence or absence of a PDGFR-neutralizing antibody. Neutralization of PDGFR in TGF-β-treated EpRas cells lead to cellular disintegration (Figure 4B), which was due to apoptosis as shown by in situ TUNEL staining (in ~75% of the cells; Figure 4C). Similarly, at concentrations corresponding to therapeutic doses used in humans (100 mg/kg), STI571 induced apoptosis in TGF-β-treated EpRas cells (Figure 4, B–D). On their own, TGF-β as well as different agents inhibiting PDGFR signaling failed to significantly induce apoptosis (Figure 4, B–D). In conclusion, TGF-β-induced EMT requires the establishment of a PDGFR/PDGFR autocrine loop, which induces PI3K signaling and protects cells from apoptosis during EMT, while Ras alone is apparently unable to do so.

Autocrine PDGFR/PDGFR signaling is necessary for maintenance of EMT in EpRasXT cells. We next addressed whether interference with autocrine PDGFR signaling would also affect mesenchymal EpRasXT cells that have completed EMT. Mesenchymal structures formed by EpRasXT cells in collagen gels and exposed to the specific PDGFR tyrosine kinase inhibitor or STI571 partially reverted to more compact, lumen-less structures, rather than undergoing apoptosis. Cells in these structures regained E-cadherin that was localized to the membrane and almost completely lost expression of 3 mesenchymal markers, i.e., vimentin, calgranulin A, and CD68 (Figure 5, A and B; ref. 29). To test whether EpRasXT cells after completion of EMT require the high PI3K activity induced by autocrine PDGF signaling for viability, EpRasXT-derived mesenchymal structures were treated with the PI3K inhibitor LY294.002, at concentrations known to reduce PI3K signaling to basal levels typical for EpRas cells (44). LY294.002 affected neither cell viability nor the mesenchymal phenotype of the cells, which maintained vimentin expression and failed to express membrane-localized E-cadherin. (Figure 5B). These results indicate that autocrine PDGFR signaling is required for maintenance of EMT, but not for survival of cells that have already undergone EMT.

PDGFR signaling is required for EMT in vivo and metastatic potential of EpRas cells. Since TGF-β-induced EMT is closely correlated to metastatic ability in EpRas cells (19) and murine tumor models (Figure 2 and refs. 11, 12), we addressed whether autocrine PDGFR signaling is also necessary for metastatic potential in vivo. For this, we generated EpRas cell clones stably expressing a dnP tagged with GFP (EpRas-dnP; Figure 6A) (45). These EpRas-dnP clones formed epithelial structures indistinguishable from those formed by parental EpRas cells, both by morphology and epithelial marker expression in collagen gels (Figure 6B). TGF-β, however, failed to induce EMT in these EpRas-dnP clones, in contrast to EpRas control cells, which underwent EMT as expected (Figure 6B). Instead, the EpRas-dnP cells formed compact structures in response to TGF-β that expressed membrane-bound, delocalized E-cadherin but no vimentin (Figure 6B), clearly resembling EpRasXT cells treated with PDGFR inhibitors (Figure 5).

EpRas-dnP cells and EpRas cells expressing GFP were injected into the mammary fat pad of nude mice, leading to tumor formation with identical incidence (data not shown) but clearly reduced tumor size (Figure 6C). Since hyperactive PI3K contributes to fast tumor growth (44), smaller tumors could be due to dnP-mediated reduced PI3K pathway activity. More detailed analysis of the tumors showed that EpRas-dnP tumors were more compact than EpRas control tumors, the tumor cells showing a less spindle-like morphology (Supplemental Figure 2). Furthermore, the (>90% cytokeratin-positive) EpRas-dnP tumor cells retained delocalized E-cadherin expression and lacked vimentin, while EpRas control tumor cells were vimentin positive but essentially lacked E-cadherin expression (Supplemental Figure 2). In conclusion, dnP expression prevents EMT in EpRas cells both in collagen gels and mouse tumors (for details, see Supplemental Figures 2 and 3).

The metastatic potential of EpRas-dnPs and EpRas cells was assayed by tail vein injection. EpRas cell–injected mice succumbed to massive lung metastases, while mice receiving EpRas-dnP cells appeared healthy even after all control animals had died. They showed no increased lung weight and revealed only rare metaasta-
PDGFR signaling might differ from those caused by neutralizing GFP mixture) contained 10–40% GFP-positive cells (Figure 7C), while respective cells from control mice (EpRas/EpRas-dnP–infected animals (Figure 7, A and B).

Thus, EpRas-dnP cells even fail to contribute to lung metastases formed by neighboring EpRas cells, showing that PDGFR signaling contributes to the metastatic potential of EpRas cells in a cell-autonomous fashion.

STI571 suppresses metastasis in tumor cells employing autocrine PDGF signaling. The effects of an overexpressed dnP on endogenous PDGFR signaling might differ from those caused by neutralizing antibodies or tyrosine kinase inhibitors. We therefore employed STI571, which effectively blocked PDGFR signaling in our cells (Figures 4 and 5) and inhibits PDGFR tyrosine kinase activity in vivo after oral administration (37). Accordingly, doses of STI571 similar to those used in humans (100 mg/kg) were fed to nude mice for 7 consecutive days, while EpRas cells were injected into the tail vein 24 hours after first administration of STI571.

All animals injected with EpRas cells but not treated with STI571 died or became moribund within an observation period of 3 weeks, while the STI571-treated mice survived this observation period, upon which they were sacrificed. The lungs of STI571-treated mice showed strongly reduced numbers of metastases as compared with untreated, EpRas-injected animals (Figure 7E). EpRas-injected control mice showed a mean lung weight nearly 1.7-fold higher, while lung weights of STI571-treated mice were only marginally increased (Figure 7F). Histological analysis showed that the STI571-treated, EpRas-injected mice exhibited a mean number of metastatic lesions per lung that was reduced nearly 3-fold compared with that of control mice (Figure 7G). Since STI571 also inhibits other tyrosine kinases besides PDGFR (42) and might thus act as a more generally cytotoxic agent, we employed a highly metastatic murine, colon carcinoma cell line CT26 (46), as a control. These cells do not upregulate PDGFR pathway genes (29) and show no response to STI571 treatment in collagen gels (see Supplemental Figure 4), in contrast to EpRas cells, in which STI571 caused apoptosis (Figure 4B). Both control and STI571-treated animals injected with CT26 cells rapidly became moribund, and all animals showed massive metastatic lesions (Figure 7E). Also, no difference in mean lung weight between treated and untreated animals was observed (Figure 7F). These results suggest that STI571 reduced the metastatic potential of EpRas cells by specific interference with the PDGFR pathway.

To address the significance of the above results in human cells, we tested 2 dedifferentiated, invasive human mammary carcinoma cell lines (MDA-MB231, CAMA-1; ref. 47; see Supplemental Figure 4) for their response to STI571 or PDGFR inhibitor. As expected, STI571 induced apoptosis in both human carcinoma lines at concentrations fully tolerated by CT26 control cells (Supplemental Figure 4B). A specific PDGFR inhibitor abolished the migratory phenotype in CAMA-1 cells, inducing compact structures instead (Supplemental Figure 4A).

Discussion

Oncogenes that hyperactivate MAPK and PI3K pathways are key players during tumor progression (19, 44). One of the major activities of these pathways is to overcome the proapoptotic and antiproliferative activities of TGF-β, which epithelial cells are subject to (7, 8, 48, 49). These oncogene-driven signaling pathways also promote local invasion and metastasis, in cooperation with TGF-β signaling (28, 30). In this article, we show that (a) oncogenic Ras alone is insufficient to hyperactivate the PI3K pathway but requires cooperation with PDGF signaling to efficiently protect mammary epithelial cells from TGF-β–induced apoptosis during EMT; (b) autocrine PDGFR signaling is required for metastasis of Ras-transformed mammary epithelial cells in a cell-autonomous fashion; (c) pathways upon histological analysis (average: 1.8 metastases per lung), compared with an average of 142.5 metastases per lung in EpRas-injected animals (Figure 7, A and B).

To determine whether the observed inhibition of metastasis by the dnP is cell autonomous, we injected nude mice with mixtures of unlabeled EpRas cells and the same cells expressing either dnP-GFP or empty GFP vectors. After 3 weeks, large lung metastases had developed in both groups of animals. However, cultured cells obtained from metastatic lungs of EpRas/EpRas-GFP-dnP–infected mice almost completely lacked GFP-positive cells (Figure 7C), while respective cells from control mice (EpRas/EpRas-GFP mixture) contained 10–40% GFP-positive cells (Figure 7C). Thus, EpRas-dnP cells even fail to contribute to lung metastases formed by neighboring EpRas cells, showing that PDGFR signaling contributes to the metastatic potential of EpRas cells in a cell-autonomous fashion.

Figure 6

dnP expressed in EpRas cells prevents EMT but not tumor growth. (A) EpRas clones infected with retroviral vectors expressing dnP-GFP (EpRas-dnP) or GFP alone (EpRas) were analyzed for expression of exogenous dnP by Western blot analysis. (B) EpRas and EpRas-dnP cells were seeded into collagen gels and treated as indicated. Results of brightfield microscopy (top panels) and staining with α-E-cadherin, α-vimentin, and α–F-actin antibodies (bottom panels) are shown. Original magnification, ×40 (B, top panels) and ×60 (B, bottom panels). (C) Cells as analyzed in A and B were injected into the fat pads of nude mice (6 mice per cell type; 2 injection sites per mouse; 2 × 10⁶ cells per injection site) and total tumor weight determined after 2–3 weeks.

Discussion

Oncogenes that hyperactivate MAPK and PI3K pathways are key players during tumor progression (19, 44). One of the major activities of these pathways is to overcome the proapoptotic and antiproliferative activities of TGF-β, which epithelial cells are subject to (7, 8, 48, 49). These oncogene-driven signaling pathways also promote local invasion and metastasis, in cooperation with TGF-β signaling (28, 30). In this article, we show that (a) oncogenic Ras alone is insufficient to hyperactivate the PI3K pathway but requires cooperation with PDGF signaling to efficiently protect mammary epithelial cells from TGF-β–induced apoptosis during EMT; (b) autocrine PDGFR signaling is required for metastasis of Ras-transformed mammary epithelial cells in a cell-autonomous fashion; (c) pathways
other than PI3K are activated by autocrine PDGFR signaling and required for maintenance of an invasive phenotype; (d) human carcinoma cell lines and samples from tumor patients confirm that autocrine PDGFR signaling may play a role in human breast cancer progression.

**Autocrine PDGFR signaling during EMT: PI3K-dependent protection from TGF-β–induced apoptosis.** During TGF-β–induced EMT of EpRas cells, an autocrine PDGF/PDGFR loop is established through upregulation of both ligands and receptors. This results in the expression of known target genes of PDGFR signaling and hyperactivation of PI3K. When attenuating PDGFR signaling with several agents including STI571 during EMT, PI3K pathway activity at basal levels was maintained. As a consequence, STI571-treated EpRas cells underwent apoptosis instead of EMT in response to TGF-β. Similar results were obtained with EpRas cells treated with the specific PI3K inhibitor LY294.002 (19). Therefore, induction of PDGF autocrine signaling at the onset of EMT cooperates with Ras to promote high PI3K activity required to protect EpRas cells from TGF-β–induced apoptosis during EMT. In contrast, EpRasXT cells after EMT did not require an autocrine PDGF loop for survival, since PI3K inhibition by LY294.002 or blockade of PDGFR signaling by respective pharmacological inhibitors do not elicit apoptosis in EpRasXT cells.

**Functional significance of other signaling pathways activated by autocrine PDGFR signaling.** Besides promoting PI3K-mediated survival during EMT, sustained autocrine PDGFR signaling contributes to maintenance of EMT. In response to 2 pharmacological PDGFR tyrosine kinase inhibitors, EpRasXT cells lost their typical spindle-shaped morphology, regained plasma membrane E-cadherin expression, and downregulated mesenchymal markers. Treatment of EpRasXT cells with the PI3K inhibitor LY294.002 elicited no comparable response, suggesting that the effect of PDGFR signaling on the mesenchymal phenotype might be due to other signaling pathways.

One such additional, EMT-specific pathway activated by autocrine PDGFR signaling involves STAT1. In EpH4-derived cells (EpC40XT) undergoing TGF-β–induced scattering (19), the basal levels of STAT1 expression were not enhanced and activated by PDGF. In contrast, cells capable of undergoing EMT (EpRasXT and EpS35XT) express elevated levels of STAT1, which are fur-
ther induced and activated by PDGF (Supplemental Figure 1). In line with this observation, numerous genes of the IFN-γ/STAT1 signaling pathways were upregulated in an EMT-specific fashion (29). Therefore, PDGF-dependent STAT1 signaling might contribute to EMT, but respective mechanisms remain to be investigated. PDGF signaling could activate NF-κB through several pathways in addition to PI3K signaling (50). It will be interesting to determine whether PDGF-dependent activation of the NF-κB pathway could contribute to EMT, including activation of many EMT-specific genes, as recently described (51).

**PDGF signaling: cell-autonomous promotion of tumor cell metastasis.** Previous work on the role of tumor cell-secreted PDGF in carcinoma progression and metastasis suggested that its main role was to elicit responses in the tumor stroma, in particular to cause tumor angiogenesis (36, 37, 52, 53). For instance, in colon carcinoma cells, TGF-β-induced PDGF was ascribed to act exclusively via paracrine effects on tumor vascularization (54). While paracrine action of PDGF on the tumor stroma is undoubtedly an important mechanism in tumor progression (36, 42, 55), our studies provide evidence for an autocrine, cell-autonomous activity of PDGF during metastasis. We showed that in vivo interference with PDGF signaling in EpRas cells injected into mice — by STI571 treatment or dnP overexpression — significantly reduced or even prevented lung metastasis. This appears to be a specific effect on the injected tumor cells, and not on other cells in the animal, as in the murine colon carcinoma cell line with a constitutive EMT phenotype (CT26; ref. 46), STI571 completely failed to affect metastasis formation. Rather than PDGF signaling, CT26 cells might employ (STI571-insensitive) VEGFR signaling for survival during EMT and metastasis, similar to colonic carcinoids that express the VEGFR Flt1 and VEGF during EMT (56). When EMT was reversed in these cells by a dominant-negative TGF-βRII (10), VEGFR rather than PDGF was downregulated (29). In line with this, human colon carcinomas show enhanced VEGF production, while agents blocking VEGFR signaling attenuated tumor growth and metastasis in mice injected with CT26 cells (57). Accordingly CT26 cells sustain STI571 treatment in culture (Supplemental Figure 4).

Several findings support our notion that PDGF inhibition abrogates metastasis formation of EpRas cells in a cell-autonomous fashion. First, a 5-day treatment with STI571 after tumor cell injection is unlikely to act via inhibition of vascularization, as the angiogenic switch only occurs after the initial tumor has exceeded a certain size. Second, STI571-mediated interference with PDGF effects on stromal or endothelial cells should have similarly inhibited metastasis formation by EpRas and CT26 cells. Most importantly, however, GFP-labeled EpRas-dnP cells failed to contribute to metastases formed by neighboring unlabeled EpRas cells. This renders a role of stromal or endothelial cells unlikely, since the EpRas cells could establish crosstalk to stromal/endothelial cells via multiple secreted factors such as chemokines (58).

The short duration of STI571 treatment able to attenuate metastasis formation by EpRas cells also makes it unlikely that inhibition of PDGF signaling would cause a proliferation defect of the EpRas cells at sites of distant metastasis. If injected EpRas cells penetrate the vascular endothelium and survive as dormant cells in the lung during STI571 treatment, they should reinitiate proliferation when drug treatment is terminated. Such dormant cells should induce numbers of smaller metastatic lesions similar to those in control mice. Since we observed a strongly reduced number of metastatic foci in STI571-treated animals, which were of a size similar to those in control mice, we favor the idea that autocrine PDGF signaling functions during extravasation in a cell-autonomous fashion.

**Cell-autonomous, autocrine PDGF signaling: relevance in mouse models and human breast cancer.** Our results in the MMTV-Neu/HER2 transgenic mouse tumor model support that autocrine PDGF signaling contributes to tumor progression and metastasis in vivo. While mammary tumors from MMTV-Neu/HER2 transgenic mice showed no evidence for EMT in vivo, respective tumors from MMTV-Neu/HER2 × MMTV-TGF-β1 mice expressed the EMT markers vimentin and tenascin C widely (Figure 2; ref. 29) and display enhanced PI3K activity (11). Importantly, in these tumors, PDGF and the PDGF target gene MCP-1 are upregulated as compared with tumors in MMTV-Neu mice, consistent with a TGF-β-induced autocrine PDGF loop.

Several lines of evidence also suggest a function of autocrine PDGF signaling in human breast cancer progression. First, STI571 and a more specific PDGFR tyrosine kinase inhibitor induced apoptosis or abolished the migratory phenotype in 2 human mammary carcinoma cell lines that exhibit a constitutive, mesenchymal EMT phenotype (47). Second, expression of both PDGFRα and PDGFRβ in human mammary carcinomas as detected by immunohistochemistry correlated with a malignant, invasive tumor phenotype, while normal breast tissue did not express these receptors. It was previously reported that elevated levels of PDGF correlate with unfavorable prognosis in human breast carcinomas (34). Increased PDGF expression was also found in late-stage breast cancer patients (35, 59). Finally, expression of both PDGF receptors (α and β) was detected in malignant breast cancer (60), pancreatic cancer, and pancreatic as well as prostate cancer cell lines (61, 62). In these cell lines, inhibition of PDGFR signaling with STI571 significantly reduced experimental metastasis in nude mice. In glioblastoma cell lines and mouse models, the importance of autocrine PDGF signaling for cancer progression is already firmly established (33, 63–65).

**STI571 as an antimetastatic drug.** Besides its main application in therapy of chronic myelogenous leukemia via BCR-ABL inhibition, STI571 (66) is increasingly used in the treatment of other diseases, including those caused by hyperactivation of the PDGF signaling pathway through gene fusion (67). Together with the clinical evidence by others (34, 35, 59), our data provide a clear functional role for autocrine PDGFR signaling in the cell-autonomous acquisition and maintenance of the metastatic phenotype of mammary tumor cells. In addition to inhibition of angiogenesis induction by paracrine PDGF signaling, PDGF inhibition by STI571 might also interfere with metastasis through cell-autonomous prevention of metastatic dissemination. Since STI571 can also inhibit tumor cell proliferation (37, 52), reactivation of dormant micrometastases might also be prevented. This would justify investigation of the potential efficacy of STI571 for mammary and other metastatic human tumors, which might rely on PDGFR signaling for tumor cell survival and dedifferentiation. As STI571 is an approved drug, it could also be included in clinical trials performed in combination with other breast cancer drugs, in the hope that it may reduce breast cancer metastasis.

**Methods**

**Cells and cell culture.** Origin and culture conditions for Eph4 mouse mammary epithelial cells, their Has-Ras transformed derivatives EpRas and EpRasXT, and CT26 colon carcinoma cells expressing or lacking dnTGF-βRII...
were described previously (10, 23). Generation and culture conditions of V12-Ras−, S35-Ras−, C40-Ras−, and Bcl-2-expressing EpH4 cells are described in ref. 19. EpRas clones expressing dnP (45) were generated similarly. The human mammary carcinoma cell lines MDA-MB-231 and CAMA-1 (a kind gift of Andreas Eger, Medical University Vienna, Vienna, Austria) were cultivated and subjected to collagen gel culture as described in Supplemental Methods.

Collagen gel culture and marker analysis. Serum-free, 3D cultures of EpRas cells and their derivatives were prepared similarly (19, 23). For description of inhibitors, growth factors, and antibodies applied, see Supplemental Methods. TUNEL assay and confocal immunofluorescence analysis was performed on 3D structures as described in ref. 19 and Supplemental Methods.

Assay for PDGF-dependent autocrine loop. Hu-PDGF-α-R-expressing murine hematopoietic cells (huPDGFR/FDCP-1) — generated as EGFR/FDCP-1 cells (68) — were obtained from BI Austria and grown in StemPro-34 plus IL-3 (2 ng/ml; R&D Systems) was used to calculate the amount of bioactive PDGF corresponding to the specific [3H]thymidine uptake (68). As a specificity control, secreted PDGF in the above supernatants was neutralized with α-PDGF-neutralizing antibody or PDGFR inhibitor. For standardization, a dilution series of purified human PDGF (0.1–10 ng/ml, PDGF-neutralizing antibody (20 ng/ml), PDGF-neutralizing antibody (20 ng/ml), PDGF inhibitor (2 μM), or ST517 (Gleevec; Novartis) (1 μM) for 30 minutes. Lysates were collected and subjected to Western blot analysis as described previously (19). See Supplemental Methods for antibodies used.

EMSA. EMSAs for STAT1/STAT3 were performed as described previously (69). For supershift reactions of STAT-containing complexes, 0.2 μg of antibodies to STAT1 (M22, Santa Cruz Biotechnology Inc.) and STAT3 (c-20; Santa Cruz Biotechnology Inc.) were employed (see Supplemental Methods for details on EMSA performance).

Tumorigenesis and metastasis assays. Athymic MF1 nude mice (6–10 weeks old) were used for mammary gland and tail vein injections as described previously (19). For details, see Supplemental Methods. All animal procedures performed were approved by the Institutional Animal Care and Use Committee of the Research Institute for Molecular Pathology and by the Bundesministerium fuer Bildung, Wissenschaft und Kultur (Vienna, Austria).

Tissue samples and immunohistochemistry. Breast cancer progression tissue microarrays included 16 normal mammary gland samples, 45 intraductal mammary carcinoma samples, and 93 invasive mammary carcinoma samples. For antibodies used and procedure details, see Supplemental Methods.

Received for publication February 4, 2005, and accepted in revised form March 21, 2006.

Address correspondence to: Hartmut Beug, Research Institute for Molecular Pathology, Dr. Bohrgasse 7, A-1030 Vienna, Austria. Phone: 43-1-79730-883; Fax: 43-1-7987153; E-mail: beug@imp.univie.ac.at. Or to: Martin Jechlinger, Memorial Sloan-Kettering Cancer Center, 1225 York Avenue, New York, New York 10021, USA. Phone: (212) 639-6193; Fax: (212) 717-3125; E-mail: jechlim@mskcc.org.

Martin Jechlinger’s present address is: Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Richard Morriggl’s present address is: Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.

Stefan Grünert’s present address is: Children’s Cancer Research Institute, Vienna, Austria.

Hartmut Beug and Stefan Grünert contributed equally to this work.

9. Cui, W., et al. 1996. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice.
13. Weeks, B.H., He, W., Olson, K.L., and Wang, X.J.


